Can a rheumatoid arthritis drug save COVID-19 patients from lung failure?
NCT ID NCT04363853
First seen Apr 09, 2026 · Last updated Apr 29, 2026 · Updated 3 times
Summary
This study tested the drug tocilizumab in 200 adults with severe or critical COVID-19 who had lung failure (ARDS). The goal was to see if the drug could improve survival and recovery. Participants received one or two doses and were followed for 30 days. Because the disease is so serious, there was no placebo group; results were compared to international reports.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Institute of Mexico
Mexico City, Mexico City, 14080, Mexico
Conditions
Explore the condition pages connected to this study.